TABLE 1.
cHP | Healthy subjects | |
Subjects n | 28 | 18 |
Females | 16 (57.1) | 10 (55.6) |
Age years | 56±11.5 | 54±12.8 |
BMI kg·m−2 | 27.2 (25.4–30.4) | 26.6 (23–28) |
Baseline dyspnoea index mMRC | 1 (1–2) | |
Smokers | 8 (29) | |
Oxygen saturation at rest % | 94±2 | |
Symptoms at diagnosis | ||
Dyspnoea | 24 (86) | |
Cough | 23 (82) | |
Wheezing | 20 (71) | |
Weight loss | 11 (38) | |
Duration of symptoms months | 24 (12–45) | |
Exposure | ||
Mould | 21 (75) | |
Birds | 18 (64) | |
Feather pillow | 6 (21) | |
Others | 3 (11) | |
No recognised exposure | 0 (0) | |
Actual exposure/previous exposure n | 4/24 | |
Pulmonary function tests | ||
FVC L | 2.03±0.65 | 3.33±0.85* |
FVC % pred | 57±17 | 89±10* |
FEV1 L | 1.75±0.52 | 2.74±0.62* |
FEV1 % pred | 61±16 | 90 ±10* |
FEV1/FVC | 0.87±0.05 | 0.82±0.04* |
FEF25–75% | 98±31 | |
TLC L | 3.37±0.90 | |
TLC % pred | 64 (53–72) | |
RV L | 1.18 (1.06–1.47) | |
RV % pred | 77 (60–88) | |
RV/TLC | 0.39±0.07 | |
DLCO % pred | 42 (31–63) | |
HRCT findings | ||
Centrilobular nodules | 3 (11) | |
Ground-glass opacities | 26 (96) | |
Mosaic pattern | 15 (54) | |
Honeycombing | 4 (14) | |
Findings suggestive of fibrosis | 25 (89) | |
Emphysema | 0 (0) | |
Bronchoalveolar lavage | 21 (75) | |
Lymphocyte count | 23 (10–38) | |
CD4/CD8 ratio | 0.57 (0.37–1.29) | |
Lung biopsy | 21 (78) | |
Transbronchial | 16 (59) | |
Surgical | 5 (19) |
Data are presented as n (%), mean±sd if normally distributed or median (25th–75th percentile), unless otherwise stated. BMI: body mass index; mMRC: modified Medical Research Council; FVC: forced vital capacity; FEV1: forced expiratory volume in 1 s; FEF25–75%: forced expiratory flow at 25–75% of FVC; TLC: total lung capacity; RV: residual volume; DLCO: diffusing capacity of the lung for carbon monoxide; HRCT: high-resolution computed tomography. *: p<0.05.